Meeting Information - The shareholder meeting is scheduled for June 27, 2025, at 14:30 [1] - The meeting will be held at the company's conference room located at 28 Lutian Road, Yuelu District, Changsha, Hunan Province [1] - Voting will be conducted through both on-site and online methods using the Shanghai Stock Exchange's voting system [1] Voting Procedures - The online voting will be available from 9:15 to 15:00 on the day of the meeting [1] - Shareholders can vote via the trading system or the internet voting platform [2] - Duplicate votes through different methods will be counted based on the first submission [4] Agenda Items - The meeting will review a proposal regarding adjustments and extensions of certain fundraising investment projects [2] - The proposal has been approved by the company's board and supervisory committee [2] Attendance Requirements - Shareholders registered by the close of trading on June 20, 2025, are eligible to attend [4] - Shareholders can appoint a proxy to attend and vote on their behalf [4] - Registration for attendance must be completed by June 24, 2025 [5] Registration Process - Registration can be done in person or via email or mail [5] - Required documents include identification and proof of shareholding [5][6] - The registration must be completed by the specified deadline to ensure participation [5] Additional Information - Attendees are responsible for their own travel and accommodation expenses [7] - Contact information for the company is provided for any inquiries [7]

证券代码：688799 证券简称：华纳药厂 公告编号：2025-059 湖南华纳大药厂股份有限公司 关于部分募集资金投资项目子项目调整 及延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 湖南华纳大药厂股份有限公司（以下简称"公司"）拟对首次公开发行 股票募集资金投资项目之"药物研发项目"中部分子项目进行调整及延期，本次 调整后，"药物研发项目"募集资金总投入额不变。 上述事项尚需提交股东大会审议。 一、募集资金投资项目概况 （一）募集资金基本情况 根据中国证券监督管理委员会《关于同意湖南华纳大药厂股份有限公司首次 公开发行股票注册的批复》（证监许可〔2021〕1966 号），本公司由主承销商 西部证券股份有限公司采用余额包销方式，向社会公众公开发行人民币普通股 （A 股）股票 2,350 万股，发行价为每股人民币 30.82 元，共计募集资金 72,427.00 万元，扣除承销及保荐费用等与发行有关的费用共计人民币 6,861.52 万元后，募 集资金净额为 65,565.48 万元。上述募 ...

证券代码：688799 证券简称：华纳药厂 公告编号：2025-060 湖南华纳大药厂股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第一次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年6月27日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票， ...

证券代码：688799 证券简称：华纳药厂 公告编号：2025-058 公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会议召开情况 湖南华纳大药厂股份有限公司（以下简称"公司"）第四届监事会第五次临 时会议于 2025 年 6 月 11 日以现场结合通讯方式召开，本次会议的通知于 2025 年 6 月 6 日送达公司全体监事。会议由监事会主席马飞先生主持，应出席监事 3 人，实际出席监事 3 人。会议的召集、召开、表决程序符合相关法律、法规及《湖 南华纳大药厂股份有限公司章程》（以下简称"《公司章程》"）的相关规定，所作 决议合法有效。 本次会议审议通过了如下议案： 表决结果：3 票同意，0 票反对，0 票弃权。 特此公告。 湖南华纳大药厂股份有限公司 第四届监事会第五次临时会议决议公告 二、监事会会议审议情况 （一）审议通过《关于部分募集资金投资项目子项目调整及延期的方案的 议案》 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的相 关公告。 湖南华纳大药厂股份有限公司监事会 202 ...

证券代码：688799 证券简称：华纳药厂 公告编号：2025-057 （一）审议通过《关于部分募集资金投资项目子项目调整及延期的方案的 议案》 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的相 关公告。 湖南华纳大药厂股份有限公司 第四届董事会第六次临时会议决议公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 湖南华纳大药厂股份有限公司（以下简称"公司"）第四届董事会第六次临 时会议于 2025 年 6 月 11 日以现场结合通讯方式召开，本次会议的通知于 2025 年 6 月 6 日送达公司全体董事。会议由董事长黄本东先生主持，应出席董事 7 人，实际出席董事 7 人。会议的召集、召开、表决程序符合相关法律、法规及《湖 南华纳大药厂股份有限公司章程》（以下简称"《公司章程》"）的相关规定，所作 决议合法有效。 二、董事会会议审议情况 本次会议审议通过了如下议案： 本议案已经第四届董事会战略委员会第四次临时会议审议通过。 表决结果：7 票同意，0 票反对，0 票弃 ...

化学制药板块短线走低，华纳药厂跌超9%，天宇股份（300702）、舒泰神（300204）、多瑞医药 （301075）、海创药业等跟跌。 ...

Group 1 - The Chinese innovative pharmaceutical industry is experiencing an unprecedented revaluation, with the innovative drug index rising over 20% and the Hong Kong innovative drug index increasing by more than 45% this year [1][2] - Institutions have shown heightened interest in the innovative drug sector, with numerous companies such as BeiGene and I-Mab being heavily researched by various institutions [1][3] - The focus of institutional research has shifted from generic drugs and raw materials to cutting-edge areas like ADCs, bispecific antibodies, and cell therapies, indicating a growing interest in clinical data and international progress [4][5] Group 2 - The recent surge in the innovative drug sector is attributed to the culmination of years of investment and development, with many projects now reaching commercialization [5][6] - The improvement in liquidity and the influx of foreign capital have significantly boosted the performance of Hong Kong innovative drug stocks, with net purchases exceeding 600 billion yuan this year [6][7] - The next three years are expected to be critical for the Chinese innovative drug industry, with 2025 marking a pivotal year for revenue growth, profitability, and valuation increases [8][9] Group 3 - The innovative drug sector is anticipated to remain a key focus within the pharmaceutical industry, with particular attention on companies that are successfully entering overseas markets and those that are experiencing significant domestic sales growth [9]

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. - A total of 373 stocks (77.9%) in the sector rose last week, while 97 stocks (20.3%) declined. The top five gainers were Shuyou Shen (60.41%), Huason Pharmaceutical (41.97%), Changshan Pharmaceutical (35.91%), Huana Pharmaceutical (32.62%), and Yifang Biological (30.51%) [4][27]. Market Performance - The pharmaceutical and biotechnology sector's performance is highlighted by the approval of 11 innovative drugs by the National Medical Products Administration (NMPA) on May 29, which enhances treatment options for patients and showcases the increasing innovation capability of China's pharmaceutical industry [5][29]. - The 2025 American Society of Clinical Oncology (ASCO) annual meeting showcased several domestic innovative drug projects, indicating that local companies are gaining international recognition for their innovative capabilities [5][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector as it is the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. Additionally, it recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services [6][35]. - Recommended stocks include Beida Pharmaceutical, Te Bao Biological, Qianhong Pharmaceutical, Ling Rui Pharmaceutical, and Lao Bai Xing. Stocks to watch include Kelong Pharmaceutical, Rongchang Biological, Kaili Medical, Huaxia Eye Hospital, and Baipu Sais [6][35].

Group 1 - The A-share innovative drug sector experienced a significant surge in the afternoon, with notable stocks such as Shutai Shen and Guanhao Bio hitting the 20% daily limit increase [1] - Nuo Si Lan De saw a substantial rise of 18%, while Warner Pharmaceuticals increased by over 17% [1] - Other companies like Ruizhi Medicine and Beilu Pharmaceutical also followed the upward trend [1]

湖南华纳大药厂股份有限公司 股票交易异常波动公告 证券代码：688799 证券简称：华纳药厂 公告编号：2025-056 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 湖南华纳大药厂股份有限公司（以下简称"公司"）股票交易连续 3 个交 易日内（2025 年 5 月 28 日、2025 年 5 月 29 日、2025 年 5 月 30 日）收盘价格 涨幅偏离值累计达到 30%，根据《上海证券交易所交易规则》《上海证券交易所 科创板股票异常交易实时监控细则》的有关规定，属于股票交易异常波动情形。 经公司自查并向控股股东、实际控制人书面发函查证，截至 2025 年 5 月 30 日，确认不存在应披露而未披露的重大事项或重要信息。 公司特别提醒广大投资者，理性决策，注意防范投资风险。 一、股票交易异常波动的具体情况 公司股票交易连续 3 个交易日内（2025 年 5 月 28 日、2025 年 5 月 29 日、 2025 年 5 月 30 日）收盘价格涨幅偏离值累计达到 30%，根据《上海证券交易所 交易规则 ...